World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 3, Number 3, June 2012, pages 97-102

Lung Cancer Screening for the Poor and Underserved: Should Routine Screening be Performed?

Figure 1. Sample of Non Small Cell Cancers. Vertical axis: percentage of total patients diagnosed in various stages; Horizontal axis: Stage of Lung Cancer; NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Isiand Jewish Hospital; US: United States.

**Table 1.** Sample of Non-Small Cell Cancers
Variable	NUMC % (#)	NSUH % (#)	LIJ % (#)	US % (#)	P-value NUMC vs. NSUH	P-value NUMC vs. LIJ	P-value NUMC vs. US
NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United States.
Stage 0-1	8.55% (30)	36.18% (246)	35.70% (136)	26.69% (26,217)	< 0.001	< 0.001	< 0.001
Stage 2-3	31.91% (112)	25.29% (172)	29.92% (114)	34.03% (33,421)
Stage 4	59.54% (209)	38.53% (262)	34.38% (131)	39.28% (38,579)
Stage 0-1	8.55% (30)	36.18% (246)	35.70% (136)	26.69% (26,217)	< 0.001	< 0.001	< 0.001
Stage 2-4	91.45% (321)	63.82% (434)	64.30% (245)	73.31% (72,000)
Stage 0-1	12.55% (30)	48.43% (246)	50.94% (136)	40.46% (26,217)	< 0.001	< 0.001	< 0.001
Stage 4	87.45% (209)	51.57% (262)	49.06% (131)	59.54% (38,579)

Table 1. Sample of Non-Small Cell Cancers

Variable

NUMC % (#)

NSUH % (#)

LIJ % (#)

US % (#)

P-value
NUMC vs. NSUH

P-value
NUMC vs. LIJ

P-value
NUMC vs. US

NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United States.

Stage 0-1

8.55% (30)

36.18% (246)

35.70% (136)

26.69% (26,217)

< 0.001

Stage 2-3

31.91% (112)

25.29% (172)

29.92% (114)

34.03% (33,421)

Stage 4

59.54% (209)

38.53% (262)

34.38% (131)

39.28% (38,579)

Stage 0-1

8.55% (30)

36.18% (246)

35.70% (136)

26.69% (26,217)

< 0.001

Stage 2-4

91.45% (321)

63.82% (434)

64.30% (245)

73.31% (72,000)

Stage 0-1

12.55% (30)

48.43% (246)

50.94% (136)

40.46% (26,217)

< 0.001

Stage 4

87.45% (209)

51.57% (262)

49.06% (131)

59.54% (38,579)

**Table 2.** Sample of Those With Adenocarcinoma
Variable	NUMC % (#)	NSUH % (#)	LIJ % (#)	P-value NUMC vs. NSUH	P-value NUMC vs. LIJ
NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United States.
Stage 0-1	9.90% (10)	45.24% (176)	40.96% (77)	< 0.001	< 0.001
Stage 2-3	24.75% (25)	20.57% (80)	28.19% (53)
Stage 4	65.35% (66)	34.19% (133)	30.85% (58)
Stage 0-1	9.90% (10)	45.24% (176)	40.96% (77)	< 0.001	< 0.001
Stage 2-4	90.10% (91)	54.76% (213)	59.04% (111)
Stage 0-1	13.16% (10)	56.96% (176)	57.04% (77)	< 0.001	< 0.001
Stage 4	86.84% (66)	43.04% (133)	42.96% (58)

Table 2. Sample of Those With Adenocarcinoma

Variable

NUMC % (#)

NSUH % (#)

LIJ % (#)

P-value
NUMC vs. NSUH

P-value
NUMC vs. LIJ

NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United States.

Stage 0-1

9.90% (10)

45.24% (176)

40.96% (77)

< 0.001

Stage 2-3

24.75% (25)

20.57% (80)

28.19% (53)

Stage 4

65.35% (66)

34.19% (133)

30.85% (58)

Stage 0-1

9.90% (10)

45.24% (176)

40.96% (77)

< 0.001

Stage 2-4

90.10% (91)

54.76% (213)

59.04% (111)

Stage 0-1

13.16% (10)

56.96% (176)

57.04% (77)

< 0.001

Stage 4

86.84% (66)

43.04% (133)

42.96% (58)

**Table 3.** Sample of Those With Squamous Cell Carcinoma
Variable	NUMC % (#)	NSUH % (#)	LIJ % (#)	P-value NUMC vs. NSR	P-value NUMC vs. LIJ
NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United States. Note: Fisher’s exact test analyses used due to small sample size for NUMC.
Stage 0-1	7.14% (4)	37.88% (50)	39.33% (35)	< 0.001	< 0.001
Stage 2-3	41.07% (23)	36.36% (48)	32.58% (29)
Stage 4	51.79% (29)	25.76% (34)	28.09% (25)
Stage 0-1	7.14% (4)	37.88% (50)	39.33% (35)	< 0.001	< 0.001
Stage 2-4	92.86% (52)	62.12% (82)	60.67% (54)
Stage 0-1	12.12% (4)	59.52% (50)	58.33% (35)	< 0.001	< 0.001
Stage 4	87.88% (29)	40.48% (34)	41.67% (25)

Table 3. Sample of Those With Squamous Cell Carcinoma

Variable

NUMC % (#)

NSUH % (#)

LIJ % (#)

P-value
NUMC vs. NSR

P-value
NUMC vs. LIJ

NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United States. Note: Fisher’s exact test analyses used due to small sample size for NUMC.

Stage 0-1

7.14% (4)

37.88% (50)

39.33% (35)

< 0.001

Stage 2-3

41.07% (23)

36.36% (48)

32.58% (29)

Stage 4

51.79% (29)

25.76% (34)

28.09% (25)

Stage 0-1

7.14% (4)

37.88% (50)

39.33% (35)

< 0.001

Stage 2-4

92.86% (52)

62.12% (82)

60.67% (54)

Stage 0-1

12.12% (4)

59.52% (50)

58.33% (35)

< 0.001

Stage 4

87.88% (29)

40.48% (34)

41.67% (25)